9M 2023 Financial Overview

9M 2023: Financial update Lundbeck narrows and raises its Adjusted EBITDA guidance FY 2023 financial guidance DKKbn Revenue Adjusted EBITDA FY 2022 actual Previous FY 2023 guidance¹) Revised FY 2023 guidance 2) 18.2 19.5-20.1 19.8-20.1 4.8 5.2-5.6 5.6-5.8 FY 2023 considerations Revenue • Strong momentum for strategic brands continues Full year positive hedging effect expected (DKK ~66m) Continued erosion of mature brands, Cipralex/Lexapro, Sabril and Deanxit impacted most Profits S&D will increase as planned due to launches R&D now expected to be slightly lower than last year mainly due to lower than expected cost related to LCM activities . Additionally, the transition from early-stage to mid-stage for several of our projects takes slightly longer than anticipated Adjusted EBITDA guidance excludes provision of Vyepti inventory obsolescence in line with prior communication 15 1) Revised guidance based on exchange rates from end of June 2023. 2) Revised guidance based on exchange rates from end of September 2023 Lundbeck

View entire presentation